Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Amphastar is a biopharmaceutical company focused on complex generic and proprietary injectable, inhalation, and intranasal products and insulin API products, and its filings offer detailed insight into how this business is structured and governed.
Investors reviewing AMPH filings will find current reports on Form 8-K that describe material events such as license agreements, contract research agreements, manufacturing and distribution amendments, and related-party transactions with entities affiliated with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. These 8-Ks outline key terms for agreements covering proprietary peptides, AMP-110, recombinant peptide research cell banks for AMP-107, and regional distribution of BAQSIMI®.
Amphastar also files earnings-related 8-Ks that furnish press releases summarizing quarterly financial results, including net revenues, net income, and non-GAAP measures such as adjusted net income and adjusted diluted EPS. These disclosures explain how the company evaluates its operating performance and reconcile non-GAAP metrics to GAAP figures.
Through Stock Titan, users can monitor real-time updates from EDGAR as new Amphastar filings appear, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available. AI-powered summaries help explain the significance of complex agreements, highlight changes in licensing and manufacturing arrangements, and surface important details about pipeline assets, manufacturing footprint, distribution partnerships, and governance matters. The filings page also makes it easier to track board and management changes, share repurchase authorizations, and other corporate actions that Amphastar reports to the SEC.
Form 4 Overview – Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen’s direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director’s reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.